| IMPDH1 Protein | |
|---|---|
| Protein Name | Inosine Monophosphate Dehydrogenase 1 |
| Gene Symbol | IMPDH1 |
| Gene ID | 3616 |
| UniProt ID | P20839 |
| PDB ID | 1JCN, 1B3R, 1ME8, 2CVD |
| Molecular Weight | 55.4 kDa (per subunit) |
| Subcellular Localization | Cytoplasm |
| Protein Family | IMPDH family, TIM barrel superfamily |
| Expression | Ubiquitous, highest in retina and brain |
IMPDH1 (Inosine Monophosphate Dehydrogenase 1) is a crucial enzyme in the purine nucleotide biosynthesis pathway that catalyzes the NAD-dependent oxidation of inosine monophosphate (IMP) to xanthosine monophosphate (XMP), representing the rate-limiting step in GTP synthesis. This enzyme is essential for de novo purine nucleotide synthesis and is particularly important in cells with high proliferative or metabolic demands, including neurons during development, synaptic activity, and photoreceptor survival. [1]
IMPDH1 exists as a tetramer, with each subunit containing a TIM barrel catalytic domain and a CBS (cystathionine β-synthase) domain pair that regulates enzyme activity through allosteric mechanisms. The enzyme requires flavin adenine dinucleotide (FAD) as a cofactor for its catalytic activity. Mutations in IMPDH1 cause retinitis pigmentosa, a progressive retinal degeneration leading to childhood-onset blindness, highlighting the protein's critical role in photoreceptor survival. Beyond retinal disease, IMPDH1 dysregulation has been implicated in Huntington's disease, Alzheimer's disease, Parkinson's disease, and various cancers, making it a therapeutic target for both neurodegenerative conditions and oncology. [2]
IMPDH1 is a tetrameric enzyme composed of four identical subunits, each approximately 55 kDa. Each monomer contains two distinct structural domains:
N-terminal catalytic domain: The larger domain adopts the TIM barrel fold (β8α8), which contains the active site. The catalytic domain includes:
C-terminal CBS domain pair: The smaller domain contains two CBS motifs that function as regulatory subunits. These domains:
The IMPDH-catalyzed reaction proceeds through a two-step mechanism:
Hydride transfer: IMP binds to the active site, and a hydride is transferred from IMP to NAD⁺, forming NADH and an intermediate (XMP hydrate)
NAD⁺ release and hydrolysis: NADH departs from the active site, and water hydrolyzes the intermediate to produce XMP
The reaction can be summarized as:
IMP + NAD⁺ + H₂O → XMP + NADH + H⁺
Key catalytic features include:
IMPDH1 plays a fundamental role in cellular metabolism by catalyzing the rate-limiting step in de novo GTP synthesis. The purine biosynthesis pathway produces IMP through a series of ten enzymatic reactions, and IMPDH1 converts IMP to XMP, which is subsequently converted to GMP by GMP synthetase. GMP can then be converted to GTP through the action of nucleoside diphosphate kinase.
GTP serves as:
In neurons, IMPDH1-mediated GTP synthesis is particularly critical for several neuronal-specific functions:
Synaptic plasticity: GTP is essential for the function of small GTPases (Ras, Rho, Rab families) that regulate:
Protein synthesis at synapses: Local translation in dendritic spines requires GTP for:
Ion channel function: Several neuronal ion channels are regulated by GTPases:
Neurons have particularly high energy demands due to:
GTP produced via IMPDH1 contributes to:
IMPDH1 is highly expressed in retinal photoreceptors, where mutations cause retinitis pigmentosa. Photoreceptors have extraordinarily high metabolic demands due to:
The high IMPDH1 expression in photoreceptors explains why IMPDH1 mutations selectively affect retinal survival despite ubiquitous expression of the enzyme. [4]
IMPDH1 dysregulation has been implicated in Alzheimer's disease through multiple mechanisms:
Purine metabolism alterations: Several studies have documented changes in purine metabolism in AD brains:
Synaptic dysfunction: GTP-dependent processes are critical for synaptic function:
Therapeutic potential: IMPDH modulation may offer neuroprotective effects:
Evidence links IMPDH1 to Parkinson's disease pathogenesis:
Dopaminergic neuron vulnerability: The high metabolic demands of dopaminergic neurons make them particularly susceptible to:
GTP synthesis impairment: Studies in PD models show:
Therapeutic targeting: IMPDH modulators are being investigated for PD:
IMPDH1 has been directly implicated in Huntington's disease:
GTP depletion: Mutant huntingtin protein:
Therapeutic approach: IMPDH activation or GTP supplementation:
New research links purine metabolism to ALS:
Metabolic dysfunction: ALS motor neurons show:
Therapeutic potential: Targeting IMPDH may offer:
Several IMPDH inhibitors have been developed for clinical use:
Mycophenolic acid: The classic IMPDH inhibitor
Tiazofurin: A nucleoside analogue
Ribavirin: An antiviral with IMPDH inhibitory activity
An alternative approach involves supplementing GTP precursors:
Inosine: A purine nucleoside that can be converted to IMP
AICAR (5-aminoimidazole-4-carboxamide ribonucleotide):
Future therapeutic directions include:
Over 40 IMPDH1 mutations have been associated with retinitis pigmentosa:
Genetic variations in IMPDH1 may influence:
IMPDH1 interacts with several cellular proteins:
IMPDH1 is central to several pathways:
IMPDH1 knockout mice are embryonic lethal, demonstrating essential function:
Tissue-specific knockouts reveal:
IMPDH activity may serve as a biomarker:
Current research areas include:
IMPDH: structure and mechanism. 2009. ↩︎